Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Overview of Bladder Cancer

Systemic Therapy for Bladder Cancer Feb 2016

Rationale for the Use of Immunotherapy in UC

Second-Line Therapy for Advanced UC Keynote-045: Pembrolizumab

Progression-Free Survival Keynote-045: Pembrolizumab

Overall Survival Keynote-045: Pembrolizumab

Overall Survival in PD-L1 Subpopulation Keynote-045: Pembrolizumab

TRAEs With Incidence ≥15%

HRQoL in Advanced UC Patients Keynote-045: Pembrolizumab

Phase 2 Study of Nivolumab in mUC CheckMate 275: Safety

Phase 2 Study of Nivolumab in mUC CheckMate 275: Efficacy

Phase 1a Study of Atezolizumab in mUC Two-Year Clinical Update

Update on Efficacy and Tolerability of Durvalumab in mUC

Phase 1b Study of Avelumab in mUC JAVELIN: Two Pooled Cohorts

Post-Platinum Treatment Summary

Treatment for Cisplatin-Ineligible mUC Patients IMvigor 210: Atezolizumab Phase 2 Study

Treatment for Cisplatin-Ineligible mUC Patients Keynote-052: Pembrolizumab Phase 2 Study

First-Line Cisplatin-Ineligible Patients Treatment Summary

Nivolumab plus Ipilimumab Treatment in mUC CheckMate 032: Efficacy

Nivolumab plus Ipilimumab Treatment in mUC CheckMate 032: Safety

Ongoing Phase 3 Studies

Immune-Related Adverse Effects

Safety Learnings From Nivolumab in Melanoma

Kinetics of Onset and Resolution of Treatment-Related Toxicities

Key Takeaways

Current Treatment Approach in the Clinic

Abbreviations

Abbreviations (cont)